OnKure signs collaboration deal with Pfizer on melanoma treatment

BOULDER — OnKure Inc. has entered into a collaboration with pharmaceutical giant Pfizer Inc. (NYSE: PFE) for a skin cancer drug combination.

In a statement Monday, the Boulder-based OnKure said it and Pfizer will work together to see through an OnKure-sponsored proof-of-concept study for its drug candidate OKI-179 in combination with Pfizer’s already-approved Mektovi drug.

Mektovi was originally developed by the formerly Boulder-based Array Biopharma, which Pfizer acquired last year for $11 billion.

OKI-179 is thought to treat skin cancers by inhibiting activity caused by a specific mutation in NRAS, a genetic…